Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma

BACKGROUND AND AIM: Currently, there is no molecular‐targeted agent that has demonstrated evidence of efficacy in patients with unresectable hepatocellular carcinoma (u‐HCC) who have developed resistance to treatment with lenvatinib (LEN). In this real‐world study, we aimed to investigate the therap...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JGH Open
Päätekijät: Tomonari, Tetsu, Sato, Yasushi, Tanaka, Hironori, Tanaka, Takahiro, Taniguchi, Tatsuya, Sogabe, Msasahiro, Okamoto, Koichi, Miyamoto, Hiroshi, Muguruma, Naoki, Takayama, Tetsuji
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Wiley Publishing Asia Pty Ltd 2020
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7731817/
https://ncbi.nlm.nih.gov/pubmed/33319048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jgh3.12408
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia